These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 35225130)

  • 1. COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Mehta-Shah N; Bartlett NL; Kahl B; Watkins MP; Dubois A; Schmelzle G; Waqar S; Ballman C; Wan F; Farnsworth CW
    Leuk Lymphoma; 2022 Jul; 63(7):1723-1727. PubMed ID: 35225130
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 vaccination in CLL: how often is enough?
    Mellinghoff SC; Cornely OA
    Blood; 2022 Dec; 140(25):2655-2657. PubMed ID: 36548017
    [No Abstract]   [Full Text] [Related]  

  • 3. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
    Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
    Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Ujjani C; Shadman M; Lynch RC; Tu B; Stevenson PA; Grainger C; Zhu H; Hill JA; Huang ML; Nielsen L; Poh C; Sorensen T; Gopal AK; Warren EH; Till BG; Lee S; Gausman D; Smith SD; Gooley T; Greninger A
    Br J Haematol; 2022 May; 197(3):306-309. PubMed ID: 35149986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Sun C
    Br J Haematol; 2022 Apr; 197(1):11-12. PubMed ID: 35029303
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
    Del Poeta G; Laureana R; Bomben R; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Nunzi A; Postorino M; Pasqualone G; Brisotto G; Steffan A; Muraro E; Zucchetto A; Del Principe MI; Gattei V
    Hematol Oncol; 2023 Aug; 41(3):559-562. PubMed ID: 36585917
    [No Abstract]   [Full Text] [Related]  

  • 7. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
    Avivi I; Luttwak E; Saiag E; Halperin T; Haberman S; Sarig A; Levi S; Aharon A; Herishanu Y; Perry C
    Br J Haematol; 2022 Mar; 196(6):1329-1333. PubMed ID: 35075635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Ujjani C; Greninger AL; Shadman M; Hill JA; Lynch RC; Warren EH; Gopal AK
    Am J Hematol; 2022 Feb; 97(2):E67-E69. PubMed ID: 34807468
    [No Abstract]   [Full Text] [Related]  

  • 9. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
    Gavriatopoulou M; Terpos E; Kastritis E; Briasoulis A; Gumeni S; Ntanasis-Stathopoulos I; Sklirou AD; Malandrakis P; Eleutherakis-Papaiakovou E; Migkou M; Trougakos IP; Dimopoulos MA
    Clin Exp Med; 2022 May; 22(2):319-323. PubMed ID: 34283338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination efficacy in patients with chronic lymphocytic leukemia.
    Wang KY; Shah P; Skavla B; Fayaaz F; Chi J; Rhodes JM
    Leuk Lymphoma; 2023 Jan; 64(1):42-56. PubMed ID: 36270021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
    Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
    Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now.
    Chatzikonstantinou T; Herishanu Y; Montserrat E; Ghia P; Cuneo A; Foà R; Scarfò L
    Cancer J; 2021 Jul-Aug 01; 27(4):328-333. PubMed ID: 34398560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
    Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
    Liebers N; Speer C; Benning L; Bruch PM; Kraemer I; Meissner J; Schnitzler P; Kräusslich HG; Dreger P; Mueller-Tidow C; Poschke I; Dietrich S
    Blood; 2022 Jan; 139(1):142-147. PubMed ID: 34669919
    [No Abstract]   [Full Text] [Related]  

  • 17. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
    Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
    Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Morawska M
    Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
    Cuneo A; Rigolin GM; Coscia M; Quaresmini G; Scarfò L; Mauro FR; Motta M; Quaglia FM; Trentin L; Ferrario A; Laurenti L; Reda G; Ferrari A; Pietrasanta D; Sportoletti P; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; Farina L; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Malerba L; Ibatici A; Tisi MC; Stefoni V; Leone M; Baratè C; Olivieri J; Murru R; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Levato L; Orsucci L; Penna G; Chiarenza A; Foà R
    Hematol Oncol; 2021 Oct; 39(4):570-574. PubMed ID: 34258787
    [No Abstract]   [Full Text] [Related]  

  • 20. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.